WallStSmart

Medtronic PLC (MDT)vsNeuropace Inc (NPCE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 35389% more annual revenue ($35.48B vs $99.99M). MDT leads profitability with a 13.0% profit margin vs -21.5%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

NPCE

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for NPCE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

NPCE1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
23.9%8/10

Revenue surging 23.9% year-over-year

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

NPCE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$450.46M3/10

Smaller company, higher risk/reward

Price/BookValuation
23.7x2/10

Trading at 23.7x book value

Return on EquityProfitability
-1.6%2/10

ROE of -1.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : NPCE

The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 23.9% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : NPCE

The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book.

Key Dynamics to Monitor

MDT profiles as a value stock while NPCE is a growth play — different risk/reward profiles.

NPCE carries more volatility with a beta of 1.86 — expect wider price swings.

NPCE is growing revenue faster at 23.9% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Neuropace Inc

HEALTHCARE · MEDICAL DEVICES · USA

NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.

Want to dig deeper into these stocks?